Friday, 6 November 2026European Markets

ARGAN And 3 Other Stocks Have Very High Payout Ratio

Loading stream...

(vianews) - elmera group (elmra.ol), argan (arg.pa), elkem (elk.ol) are the highest payout ratio stocks on this list.

we have congregated information regarding stocks with the highest payout ratio up to now. the payout ratio in itself isn't a promise of good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

when investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.

1. elmera group (elmra.ol)

1363.64% payout ratio

earnings per share

as for profitability, elmera group has a trailing twelve months eps of kr2.07.

pe ratio

elmera group has a trailing twelve months price to earnings ratio of 15.97. meaning, the purchaser of the share is investing kr15.97 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.02%.

yearly top and bottom value

elmera group's stock is valued at kr33.05 at 11:10 est, way higher than its 52-week high of kr24.44.

more news about elmera group.

2. argan (arg.pa)

78.75% payout ratio

earnings per share

as for profitability, argan has a trailing twelve months eps of €4.

pe ratio

argan has a trailing twelve months price to earnings ratio of 17.35. meaning, the purchaser of the share is investing €17.35 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.67%.

revenue growth

year-on-year quarterly revenue growth grew by 7.4%, now sitting on 229.78m for the twelve trailing months.

moving average

argan's value is under its 50-day moving average of €76.08 and way under its 200-day moving average of €77.19.

more news about argan.

3. elkem (elk.ol)

77.32% payout ratio

earnings per share

as for profitability, elkem has a trailing twelve months eps of kr-0.8.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.37%.

revenue growth

year-on-year quarterly revenue growth declined by 26.2%, now sitting on 39.82b for the twelve trailing months.

yearly top and bottom value

elkem's stock is valued at kr18.70 at 11:10 est, way below its 52-week low of kr22.30.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 2, 2023, the estimated forward annual dividend rate is 6 and the estimated forward annual dividend yield is 25.91%.

more news about elkem.

4. frontline (fro.ol)

40.94% payout ratio

earnings per share

as for profitability, frontline has a trailing twelve months eps of kr29.18.

pe ratio

frontline has a trailing twelve months price to earnings ratio of 8.11. meaning, the purchaser of the share is investing kr8.11 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.1%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 15, 2023, the estimated forward annual dividend rate is 20.26 and the estimated forward annual dividend yield is 10.59%.

volume

today's last reported volume for frontline is 394507 which is 50.1% below its average volume of 790628.

earnings before interest, taxes, depreciation, and amortization

frontline's ebitda is 192.84.

more news about frontline.

1. 1 (1)

1% payout ratio

1

earnings per share

as for profitability, 1 has a trailing twelve months eps of €1.

pe ratio

1 has a trailing twelve months price to earnings ratio of 1. meaning, the purchaser of the share is investing €1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.

earnings before interest, taxes, depreciation, and amortization

1's ebitda is 1.

sales growth

1's sales growth is 1% for the ongoing quarter and 1% for the next.

volatility

1's last week, last month's, and last quarter's current intraday variation average was 1.00%, 1.00%, and 1.00%.

1's highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).

more news about 1.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com